214 related articles for article (PubMed ID: 32856720)
21. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
22. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
[TBL] [Abstract][Full Text] [Related]
24. Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.
Liu FF; Shi W; Done SJ; Miller N; Pintilie M; Voduc D; Nielsen TO; Nofech-Mozes S; Chang MC; Whelan TJ; Weir LM; Olivotto IA; McCready DR; Fyles AW
J Clin Oncol; 2015 Jun; 33(18):2035-40. PubMed ID: 25964246
[TBL] [Abstract][Full Text] [Related]
25. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
27. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Turashvili G; Brogi E; Morrow M; Hudis C; Dickler M; Norton L; Wen HY
Breast Cancer Res Treat; 2017 Aug; 165(1):65-76. PubMed ID: 28577081
[TBL] [Abstract][Full Text] [Related]
28. Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.
Yamanouchi K; Kuba S; Eguchi S
Surg Today; 2020 Jul; 50(7):657-663. PubMed ID: 31190183
[TBL] [Abstract][Full Text] [Related]
29. PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.
Lattanzio R; Iezzi M; Sala G; Tinari N; Falasca M; Alberti S; Buglioni S; Mottolese M; Perracchio L; Natali PG; Piantelli M
BMC Cancer; 2019 Jul; 19(1):747. PubMed ID: 31362705
[TBL] [Abstract][Full Text] [Related]
30. Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer.
Casey MC; Prakash A; Holian E; McGuire A; Kalinina O; Shalaby A; Curran C; Webber M; Callagy G; Bourke E; Kerin MJ; Brown JA
BMC Cancer; 2019 Jul; 19(1):712. PubMed ID: 31324173
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
32. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
35. ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.
Magnusson K; Gremel G; Rydén L; Pontén V; Uhlén M; Dimberg A; Jirström K; Pontén F
BMC Cancer; 2016 Nov; 16(1):904. PubMed ID: 27863473
[TBL] [Abstract][Full Text] [Related]
36. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
37. Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers.
Takahashi H; Oshi M; Asaoka M; Yan L; Endo I; Takabe K
Ann Surg Oncol; 2020 Oct; 27(11):4475-4485. PubMed ID: 32436191
[TBL] [Abstract][Full Text] [Related]
38. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
39. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
40. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
